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Objective: Pharmacists have adopted an active role on asthma management. We aimed to 
analyze the intervention dose, understood as the “amount of program delivered”, and core 
components of the intervention provided by pharmacists on asthma management.   
Data sources: A literature search was conducted in December of 2016 at PubMed since its 
inception. 
Study selection: A two stage approach was used. At the first stage systematic reviews of 
pharmacists’ interventions on asthma management were identified. At the second stage primary 
studies included in the systematic reviews were selected. 
Data extraction: The DEPICT-2 (Descriptive Elements of Pharmacist Intervention 
Characterization Tool) was used for data extraction. In addition GINA (Global Initiative for 
Asthma) guidelines were used as a reference to classify the interventions’ core components. 
Results: 31 studies were included .In most of the studies the pharmacist-patient intervention 
occurred at the community pharmacy setting (n=22). The most common core components 
used in pharmacists’ interventions were the provision of drug information and patient 
counselling (n=27). Pharmacists’ interventions frequently were target at assessing and 
improving the use of patient’s inhaler technique (n=27). Educational materials and written 
action plans were the materials most commonly used in the interventions (n=20). The 
duration (n=13) and the frequency (n=16) of the intervention were the most frequent 
information about the intervention dose measure reported. 
Conclusion: Pharmacists’ interventions in asthma management are complex. Structured 
educational programs and patient counselling appear to be the most frequent core component 
of the pharmacist’s interventions. Interventions were focused on the provision of information 
about the condition and on inhaler technique assessment and training. However, the majority 
of studies failed to report the intervention dose sufficiently to be reproduced. The reporting of 
this indicator is crucial to ensure the reproducibility of the interventions assessed and their 








 Asthma is a major health problem affecting 300 million people worldwide with a high 
prevalence in developed countries. 
 Complex interventions, defined as “interventions that contain several interacting 
components”, delivered by health care professionals are used as a strategy to reduce 
the burden of chronic diseases.  
 Pharmacists have an important role in the treatment of the condition to achieve 
positive outcomes. However the intervention complexity is difficult to report. 
Therefore, their core components and dose remain heterogeneous. 
Findings: 
  Most of pharmacists’ interventions are targeted at providing information about the 
condition and inhaler technique assessing and training. 
 Medication adherence is an essential core component that should be included in all 
asthma management intervention delivered by pharmacists. 
















Asthma is a major health problem affecting 300 million people worldwide with a high 
prevalence in developed countries.1 Ineffective management of the disease is common, mostly 
due to medication non-adherence, poor inhaler technique or exposure to triggers. 2, 3 The Global 
Initiative for Asthma (GINA) is a leading medical guidelines organization whose main 
objective is to reduce asthma prevalence, morbidity, and mortality, providing the foundation 
for asthma guidelines worldwide. Since its first report in 1993 it has been updated on a yearly 
basis with a major significant update in 2006, signaling a paradigm shift in asthma 
management, from asthma severity to asthma control. Consistent education delivered by a 
healthcare provider, with patient active participation, is a critical component recommended by 
GINA for effective asthma management and good asthma control.  
Following these recommendations, different health care providers including pharmacists have 
adopted an active role in the management of the condition through the provision of complex 
interventions.4,5 Complex interventions have been defined as “interventions that contain 
several interacting components”.6 The complexity of these interventions may be driven by the 
number and variability of the intervention’s components, the number of individuals targeted 
by the intervention, the level of behavioral change required in the provider and patient, and/or 
how the interventions’ components interact.6 There is an increasing body of evidence 
supporting the positive impact of these interventions for asthma patient care in controlled 
studies.7-9 When these evidence-based complex interventions are replicated or finally 
implemented into routine practice, it is crucial not only to know whether they are effective, but 
also which interventions’ core components (i.e. “active ingredients of the intervention”), are 
essential in making them effective. Thus, if an intervention is not achieving its expected 
outcomes, an evaluation can be made to understand whether the intervention is ineffective in 
nature or whether it was not implemented correctly. However, as researchers often select 
different sets of indicators to describe the interventions’ core components,10 replication in 
practice and comparison across studies can be challenging. From an implementation science 
point of view, intervention dose  (understood as the “amount of program delivered”,11 i.e. 
intensity and frequency of the intervention)  is also crucial to understand its effectiveness and 
in achieve successful implementation.  The intervention dose has been found to be a potential 




be effective in controlled studies may not achieve their desired outcomes in daily practice if 
they are not being delivered with the correct intervention dose. 
Although pharmacists’ interventions have a positive effect on a range of different asthma 
outcomes,13 there seems to be a high heterogeneity in the core components and characteristics 
of the interventions delivered. The identification of the interventions’ core components and 
their dose is needed to provide a foundation for the design of new pharmacist interventions on 
asthma management and successfully implement interventions proven to be effective in impact 
studies. Furthermore, how pharmacists are reporting information about the core components 
will be useful to detect what information is essential to replicate these interventions and what 
information could be missing.    
Therefore, our objective was to analyze the core components and the dose of the interventions 
provided by pharmacists in asthma management.  
METHODS 
Literature search and screening 
A systematic review was conducted following the reporting and methodological standards 
recommended by PRISMA14 and Cochrane.15 A two-stage literature search was undertaken in 
December of 2016. The first stage aimed to identify systematic reviews on pharmacists’ 
interventions of asthma management. A PubMed search, which includes MEDLINE, PubMed 
Central, and other NIH databases, was conducted since its inception (table 1). Two 
researchers (CCG and FFL) independently screened all titles and abstracts to exclude 
irrelevant records. Next, a full-text eligibility process was undertaken using the following 
exclusion criteria:  1) non-systematic and systematic reviews assessing pharmacists’ 
interventions on patients with other conditions different to asthma.  
During the second stage, all the primary studies included in the systematic reviews selected 
during the first stage were gathered. A full-text analysis was independently performed by two 
researchers (CCG and VGC). The following exclusion criteria were applied: 1) papers 
screening or assessing asthma control without further management, 2) papers in which the 
intervention was provided simultaneously by a pharmacist and another health care professional, 




commentaries, 5) papers reporting interventions provided to patients with other respiratory 
conditions different to asthma, 6) papers not written in languages with roman characters. 
Duplicate papers were removed. This review was registered in the PROSPERO International 
prospective register of systematic reviews database (registration CRD42016029181). 
Data extraction and synthesis 
The DEPICT-2 (Descriptive Elements of Pharmacist Intervention Characterization Tool)16 was 
used to guide the data extraction .The DEPICT-2 is a tool that aims at guiding authors when 
describing and characterizing pharmacists’ interventions. It is composed by 146 items grouped 
into eleven domains: contact with recipient, setting, focus of the intervention, clinical data 
sources, variables assessed, action(s) taken by the pharmacist, timing of action(s), materials 
that support actions, repetition, communication with recipient, and changes in therapy and lab 
tests.16 Two DEPICT-2 domains, ‘Action undertaken by the pharmacist’ (8 items) and 
‘Materials that support actions’ (9 items) (table 2) were used to extract the information on the 
interventions’ core components. To better characterize the interventions delivered, GINA 
guideline was used as a reference due to the fact that it is updated yearly and used worldwide. 
In 2006 GINA as stated above, adopted a new asthma management approach, based on asthma 
control rather than asthma severity or symptoms. In this update, the relevance of establishing 
a patient-doctor partnership, the importance of setting individual treatment goals, patient self-
management, avoiding trigger factors and the appropriate treatment of other comorbidities 
were also introduced. Therefore, the interventions’ core components were classified in two 
groups: (1) core components of interventions delivered prior 2006 and (2) core components of 
interventions delivered since 2006. The figure 2 summarizes the general characteristics of the 
pharmacists’ interventions on asthma management. The information about the studies included 
and the intervention dose is retrieved in appendix 1 available on JAPhA.org as supplemental 
content. 
RESULTS 
Initially, twenty-six records were identified. Three of them were systematic reviews of 
pharmacists’ interventions on asthma patients.13,17,18 These three systematic reviews included 
forty-nine papers. After the screening process, forty-two articles were selected for full-text 
review and 31 studies were included in the analysis (Figure 1). These studies were conducted 




Finland,36 Belgium,37 France,38 Spain,39 Sudan,40 India,41 Denmark,42 Bulgaria,43 Italy,44 
Chile,45 Taiwan,46 United Kingdom,47 Brazil,48 and New Zealand.49  
Core components of the interventions performed by the pharmacists  
Core components of interventions delivered prior 2006 
A. Structured educational programs 
Two studies comprised of structured patient educational programs.29,43 One of them29 focused 
on asthma disease, asthma treatments, the use of asthma devices, and inhaler technique. The 
other43 was based on providing information about the condition, possible asthma 
complications, and adverse drug reactions. In addition, pharmacists explained to patients the 
effects of obesity and nicotine in this disease. Inhaler technique training and peak flow meter 
use were used as part of the program. The patients received a self-monitoring device, 
educational material and written instructions on inhaler technique,29 or  educational material 
and a self-monitoring patient diary.43  
B. Drug information provision or patient counselling 
 In fourteen studies, pharmacists delivered counselling sessions.23,28,31-36,42,44-47,49 Information 
about the disease,31-33,35,36,42,47 the way to recognize and manage asthma trigger factors23,31, 
35,44,47 as well as  asthma symptoms,31,36,44,47 the medication used to treat the disease31,33,35,42 
and the adherence to treatment23,42 were the topics covered in these sessions. The main actions 
performed by the pharmacists within the studies were: goal setting with the patients,23 assessing 
and correcting the patients inhaler technique,23,28,31-34,36,42,44-47 and instructing the patients in 
the used of the peak flow meter.23,31-33,35,36,44,46,47 In order to reinforce the counselling session, 
some materials were provided such as diaries to record peak flow measures and asthma 
symptoms,23,31-33,35,36,42,44,46,49 portable peak flow meters,31-33,35,36,42,44 handouts with 
information about different asthma issues,34,45-47 or in one case written instructions about the 






C. Referral to other HCP  
Pharmacists referred patients to other health care professionals in 5 studies.32,34,42,44,49 In some 
of the interventions referrals were made when the patients needed additional drug therapy,32 
change of their treatment,44 or if the pharmacist suggested to patients to visit their physician 
for reassessment.34 A referral letter49 and a medication list34  with the referral letter were given 
to the patient in  two studies.  
D. Change or suggestion for change in therapy 
In seven studies pharmacists made recommendations to other HCPs to suggest a more 
appropriate treatment or a different dosage of the patient’s medication.23,32,33,35,36,44,47 
Pharmacists recommended a treatment modification when they identified a more appropriate 
inhaler device or when clinical asthma outcomes signaled medication ineffectiveness.23,32,33, 
35,44 The pharmacist recommended a change of treatment directly to the patient in one study.47 
E. Monitoring results report 
In one study, pharmacists monitored patient asthma control indicators and provided the 
information obtained to the physician.27 No further materials were used.  
Core components of interventions delivered since 2006 
A. Structured educational programs 
In one study25 the pharmacist provided an educational program based on asthma, it´s 
management, and the medication used. The correct used of the inhaler device was taught. 
Moreover, the pharmacist provided a written asthma action plan and the relevant information 
in pamphlets and leaflets.25 
B. Drug information provision or patient counselling 
Thirteen studies performed counselling sessions.19,20,22,24,26,27,30,37-41,48 Information about 
asthma pathology 19,22,27,37,40,41 and the medication used to treat it 19,22,24,30,37,40,41 was provided  
in some of them. The adherence to the treatment19,22,24,37,39 as well as asthma triggers22,27,37 and 




Goal setting in collaboration with the patient was another action performed by the pharmacists 
in some studies,19,20,22 moreover they identified patient’s drug-related problems.19,30 Smoking 
cessation advice was included as part of the session in one study.27 The materials used in some 
sessions were wordbooks with information about the disease and in which patient’s goal were 
settled,20 cards to records patient symptoms,40 written  personalized instructions for each 
patient,38 protocol based intervention,39 and a  portable spirometer.27 
C. Referral to other HCP 
In seven interventions the pharmacists referred their patients to other health care 
professionals.19-22,27,30,37 They were referred if they didn’t have an asthma action plan,19, 22 or if 
they had a  suboptimal spirometry exam.19,22,37 Other causes for referring were if a medication 
review was needed20,22 or if they hadn´t had any review six months before the intervention.19,22 
When severe asthma related-problems were identified30 or if a new prescription was needed,27 
the pharmacists suggested to the patient to visit their physician .A referral letter was used in 
two studies.21,22  
D. Change or suggestion for change in therapy 
In three studies, pharmacists made recommendations to other HCPs to suggest a more 
appropriate treatment or a different dosage of the patient’s medication.27,40,48 Pharmacists 
contacted other HCPs if they identified medication ineffectiveness27 or if they wanted to inform 
them about a more effective dosage or treatment for the patients.40,48 Medication reconciliation 
lists were provided to the physician in one study.48 
E. Monitoring results report 
The pharmacists monitored patient asthma control indicators and provided feedback to the 
patient and the physician.27 No further materials were used.  
In one study, the intervention was based on a computer program installed in several pharmacies 
without a direct interaction between the pharmacist and the patient.21 Based on this program, 
educational material about asthma, a referral letter for the patient general practitioner, and the 





Twenty-seven out of thirty-one studies reported some information about the intervention 
dose.19,20,22-25,27,29-34,36-49 The duration (n=13; 48.19 %)20,22-25,29,31,38,42,45-47,49 and the frequency 
(n=16 ; 59,26%)19,20,23,24,30-33,36,37,39-44 of the intervention were the most frequent intervention 
dose measurements reported. Other content reported about the intervention dose was: the 
percentage of patients referred to another HCP (n=4; 14.81%),19,27,34,49 the number of patients 
receiving different types of goals (n=3; 11.11%),19,20,23 the number or percentage of patients 
who were the recipients of the different types of interventions delivered (n=3; 11.11%),19,34,48 
the percentage of patients with medication changes (n=2;7,40%),27,36 number of interventions 
related to changes in patients medications (n=2; 7,40%),40,48 the number of the different types 
of the intervention delivered (n=1; 3.70%),40 and time spent reviewing the medication (n=1 ; 
3.70%,).22  A description of the intervention dose can be found in appendix 1, available on 
JAPhA.org as supplemental content. 
The use of statistical techniques to correlate intervention core components, intervention dose 
and asthma outcomes was attempted. However, this analysis could not be performed due to the 
high heterogeneity in the core intervention components and asthma outcome indicators 
reported.  
DISCUSSION  
Thirty-one studies reporting pharmacists’ interventions on asthma management were analyzed. 
The type of interventions delivered varied between studies. However, many of them had similar 
characteristics. Interventions were primarily conducted during one-to-one sessions.19-24,26-28,30-
42,44-49 Whether individual interventions are more likely to optimize an improvement in 
patient’s health outcomes remains unknown. Nevertheless, it allowed providers to focus on 
individual patient’s needs and target them more effectively with their intervention. The 
interventions were mainly delivered in a community pharmacy setting, 29,30,32-36,41-49,52-54,57-59 
suggesting community pharmacists can be a feasible point-of-asthma care education due to 
their accessibility, regular contact with the patient and proven effectiveness in asthma care. 
The DEPICT-2 was used to systematically extract and analyze the interventions core 
components of the studies included, providing more consistency to our results. This reliable 
tool has been previously tested and used to analyze 269 randomized controlled trials describing 
pharmacist’s interventions in the management of other chronic diseases. Drug information 




pharmacists’ interventions.19,20,22-24,26-28,30-42,44-49 It is highly likely these types of actions are the 
most suitable to be delivered by pharmacists in primary care settings. They fit with the current 
role of pharmacists in the management of chronic conditions, they have proven to have positive 
effect on patient outcomes, and they are well accepted by patients, making them feasible to be 
implemented. They are focused on several important aspects of the disease and are usually 
modified to be targeted at the patient’s needs.  Counselling and drug information sessions cover 
essential information about the disease and its management, such as the way in which asthma 
medications should be used and the problems arising from their improper use. Moreover, they 
are usually focused on improving self-care behaviors, providing patients with the fundamental 
skills to self-manage their condition. Patient’s self-efficacy has been proven to be fundamental 
to prevent the worsening of asthma symptoms and asthma exacerbations.50 This is usually 
caused by drug related problems including inappropriate use of inhalers or medication non-
adherence. Inhaler technique assessment and training19,22-47 was identified to be a core target 
in most of the interventions in the studies included in this review. This seems reasonable as 
there is extensive evidence linking poor inhaler technique with improper asthma control.51-53  
Interestingly, a high percentage of the studies reported patient referral to another health care 
professional.19-22,27,30,32,34,37,42,44,49 This result may be explained by the evolution towards a more 
integrated multidisciplinary model of care, in which different health care professionals interact 
to improve patient care. In the case of pharmacist-physician collaboration, it seems reasonable 
that these interactions can contribute to an optimization of clinical outcomes and health care 
costs.  
In regards to the educational resources used during the interventions assessed, pharmacists used 
different types of educational materials or written action plans in most of the studies.20,21,23,25-
31,34,38,39,41,43-48 It can therefore be assumed that the use of these resources may improve the 
patient’s understanding of the recommendations provided ensuring they follow them once the 
interaction with the pharmacist is over. We recommend the use and provision of educational 
materials that align with the interventions’ core components. The use of these materials can 
reinforce the intervention delivered and can guide the patient once the interaction with the HCP 
is finished. 
The latest version of GINA guidelines54 state interventions for asthma management should 
include: the provision of information about the disease, how to avoid trigger factors, the 




management skills with the use of asthma action plans according to patients’ needs. In our 
review we found there were minimal differences in the core components of those interventions 
reported prior to 2006 with those reported since 2006. In the last decade, pharmacists’ role in 
asthma management has evolved towards a more active and patient centered care. However, 
the implementation and integration of those changes into routine practice seems to be a slow 
process. Medication adherence, it is currently one of the most important core components for 
asthma management, reaching a significant relevance since the GINA report in 2006.55 
Surprisingly this core component was only delivered in two23,42 studies before the year 2006 
and five19,22,24,37,39 after the year 2006. It is now widely known that medication adherence to 
maintenance therapy is essential to the achievement of asthma control. Therefore any 
pharmacist intervention on asthma management should incorporate this core component, 
identifying practical and behavioral specific barriers and addressing them accordingly in an 
individualized and targeted manner.54  
As previously reported, most of the studies reported some information about the intervention 
dose.29,30,32-35,37,39-44,46-59 The intervention dose measurements most frequently reported were 
the duration20,22-25,29,31,38,42,45-47,49 and the frequency19,20,23,24,30-33,36,37,39-44 of the intervention. 
However, these intervention dose measurements differed in the way they were reported. A 
good example of the intervention dose reporting is the study conducted by Stergachis31 et al, 
who assessed the percentage of patients receiving different intervention’s components and their 
duration. Other important intervention dose measurement used included the number of 
different types of interventions provided,40 the percentage of patients who were the recipients 
of the different types of interventions delivered,19,34,48 and  the number of patients receiving 
different types of goals.29,30,33 The reporting of this information can assist researchers and 
implementers in evaluating the impact of each intervention component on different clinical 
outcomes, the suitability of the intervention according to the patient’s characteristics, or even 
in allowing its replicability during the implementation phase. Furthermore, it can guide authors 
on targeting asthma interventions according to the patient’s needs, which appears to be a more 
effective approach for achieving optimal outcomes than standard strategies. The percentage of 
patients referred29,37,44,59 was another intervention dose measurement used which can prove the 
importance of inter-professional collaboration in optimizing patient care, showing how often 
pharmacists can screen and refer patients when required. Due to their regular interaction with 
asthma patients, pharmacists are in an excellent position to identify drug related problems and 




effective referral criteria and referral systems should be developed and implemented. In 
addition, the number of interventions made to change or modify patients therapy40,48 or the 
number of patients that actually got a change in their therapy27,36 were  intervention dose 
measurement used in some studies. This information is essential in terms of the study 
outcomes, since it may be able to influence some of the outcomes achieved. However, some 
studies included in our systematic review did not report any dose indicators for this type of 
intervention.26,31,33,40 
Adequate reporting of health interventions is an essential process contributing to the practice 
of any health care profession. It allows the replicability and implementation of effective 
evidence-based interventions. However, poor reporting of complex interventions targeted at 
different medical conditions seems to be a common problem. For example, an in depth analysis 
of studies published in nursing research journals showed that most authors failed to provide a 
comprehensive description of the intervention to allow its replication.56 The same issue is 
usually identified when reporting the intervention dose. This was highlighted in a recent 
systematic review aimed at summarizing the evidence of pharmacists’ interventions on patients 
with chronic kidney disease and at assessing their implementability.57 The authors concluded 
that additional information should be reported in order to facilitate the implementation of those 
interventions in practice. This included an in depth description of the resources used to develop 
the intervention, the materials provided to both patients and practitioners, and the intervention’s 
protocol and procedures. A similar problem was highlighted in another systematic review 
summarizing asthma management interventions provided by different health care 
professionals. The authors found there was a lack of information on both the duration and 
frequency of the interventions provided and a high variability amongst the training 
characteristics and the materials provided.58 Moreover, the identification of the interventions’ 
core components remained a challenge, also suggesting there is a lack of consensus on the most 
effective education strategies in asthma management.  
As it has been suggested,59 reporting intervention core components would allow the 
identification of its “effective ingredients” and its optimization over time. In addition, the 
intervention dose should also be standardized. The more detail in the dose reporting, the more 
reproducible an intervention will be. Reporting the number of patients undergoing a specific 




patients receiving a specific time or number of a given action would allow creating a clearer 
picture of what the intervention consisted of. 
LIMITATIONS 
In our systematic review, primary studies were identified through previously published 
systematic reviews of pharmacist’s interventions on asthma management. Some studies not 
included in these reviews could be missing in our analysis. Moreover some factors could have 
influenced the amount of information reported in the studies analyzed, including the word limit 
of some journals, but it is important to highlight the main reason to publish a study is ensuring 
the reproducibility of the intervention performed. 
CONCLUSION 
Pharmacists’ interventions in asthma management are complex and include several interacting 
components. Structured educational programs and patient counselling appear to be the most 
frequent component of the pharmacist’s interventions. These sessions were focused on the 
provision of information about the condition and on inhaler technique assessment and training. 
Following GINA guidelines, the interventions’ core components reported prior 2006 with those 
reported since 2006 do not present major differences. However, medication adherence was not 
included as core component in most studies. Intervention’s frequency and duration were the 
intervention dose measurement most commonly used. The majority of studies failed to report 
the intervention dose sufficiently to be reproduced. The reporting of this indicator is crucial to 
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